poisar

Stocks · News reference

Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks

Benzinga Newsdesk

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator,

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VOR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Vor Bio announced the grant of stock options for 59,250 shares and RSUs for 12,550 shares to 9 newly hired employees on October 1, 2026, as material inducements to employment. The options have a 10-year term with an exercise price of $18.06 per share and vest over four years. The company continues advancing telitacicept through Phase 3 clinical development for autoimmune diseases, with enrollment completed in the UPSTREAM MG trial and expansion into ocular myasthenia gravis.

    VOR